Health care investors in Cambridge, Massachusetts
Updated 16 Nov 2026
Venture funds
4 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Mission BioCapital Mission BioCapital invests in early-stage life science companies, with recent investments including Circle Pharma and Cloverleaf Bio. Cambridge, United States |
Biotech, Health care | Seed, Early stage venture, Late stage venture | 20% | 4 |
| 2 | F-Prime F-Prime invests in healthcare and technology, with recent companies including Albert Invent and Nocion Therapeutics. Cambridge, United States |
Health care, Fintech | Seed, Early stage venture, Late stage venture | 25% | 3 |
| 3 | Mass General Brigham Ventures Mass General Brigham Ventures is the venture arm of Mass General Brigham, investing in early-stage companies, with recent investments including Claris Biotherapeutics and InStride Health. Cambridge, United States |
Health care, Biotech | Seed, Early stage venture | 10% | 2 |
| 4 | The Engine The Engine supports new companies working on scientific and technological innovation, with recent companies including Hyperlight and Emvolon. Cambridge, United States |
Hardware, Health care | Seed, Early stage venture | 36% | 2 |
Table 1. Health care investors in Cambridge, Massachusetts: venture capital and micro VC funds ranked by health care companies whose most recent round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| F-Prime | Venture capital firm | Cambridge, United States | •••@fprimecapital.com | |
| Atlas Venture | Venture capital firm | Cambridge, United States | •••@atlasventure.com | 857 20••• |
| Founder Collective | Venture capital firm | Cambridge, United States | •••@foundercollective.com | (617) ••• |
| Mission BioCapital | Venture capital firm | Cambridge, United States | •••@missionbiocapital.com | +1 617••• |
| MIT delta v | Startup accelerator | Cambridge, United States | •••@mit.edu | 617-25••• |
| The Engine | Venture capital firm | Cambridge, United States | •••@engine.xyz | |
| Waterline Ventures | Venture capital firm | Cambridge, United States | •••@waterlineventures.com | (857) ••• |
| Flint Capital | Venture capital firm | Cambridge, United States | •••@flintcap.com |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
| Firm | Person | Title | Verified email | |
|---|---|---|---|---|
| F-Prime | S••• J••• | General Partner and Co-Founder, Investing in AI Native Software | s•••@fprimecapital.com | In the CSV |
| Atlas Venture | B••• B••• | Partner | b•••@atlasventure.com | In the CSV |
| Founder Collective | A••• H••• | General Partner | a•••@foundercollective.com | In the CSV |
| Mission BioCapital | S••• T••• | Managing General Partner | s•••@missionbiocapital.com | In the CSV |
| Matrix | D••• S••• | General Partner | d•••@matrix.vc | In the CSV |
5 verified partner contact rows from organizations on this list, names and emails masked.
- 19 of the 26 health care investors in Cambridge, Massachusetts have a published email address, 18 a phone number and 26 a website.
- F-Prime has the most recorded investments, 540, 133 of them as lead investor.
- 14 of them are investors in at least one company that closed its most recent round in the last 12 months.
- Founder Collective is an investor in 5 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is T-Therapeutics' $133.0M Series B on 5 November 2026.
- Software is the most common sector across their 573 portfolio companies (76%).
- Early stage venture is the most common investment stage, recorded for 24 of them (92%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Health care investors in Cambridge, Massachusetts
26 of 26, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F-Prime | Venture capital firm | Cambridge, United States | Health care, Fintech | T-Therapeutics, Albert Invent, Immuneel Therapeutics | 4 | 540 | 133 | 113 | •••@fprimecapital.com | In the CSV | |
| 2 | Johnson & Johnson Innovation | Corporate venture arm | Cambridge, United States | Health care, Biotech | ONL Therapeutics, Flindr Therapeutics, Asgard Therapeutics | 118 | 39 | 26 | In the CSV | |||
| 3 | Atlas Venture | Venture capital firm | Cambridge, United States | Health care, Biotech | Diagonal Therapeutics | 1 | 638 | 179 | 199 | •••@atlasventure.com | 857 20••• | In the CSV |
| 4 | Founder Collective | Venture capital firm | Cambridge, United States | Artificial intelligence, Commerce | Baselayer, WHOOP, Ownwell | 5 | 543 | 35 | 161 | •••@foundercollective.com | (617) ••• | In the CSV |
| 5 | Mission BioCapital | Venture capital firm | Cambridge, United States | Biotech, Health care | Circle Pharma, Cloverleaf Bio, Integrated Biosciences | 4 | 85 | 17 | 19 | •••@missionbiocapital.com | +1 617••• | In the CSV |
| 6 | Matrix | Venture capital firm | Cambridge, United States | Hardware, Artificial intelligence | Houmo.AI, Ampersand, Outset | 4 | 585 | 190 | 151 | (617) ••• | In the CSV | |
| 7 | MIT delta v | Startup accelerator, University program | Cambridge, United States | Hardware, Health care | VideaHealth, VSPARTICLE, TracFlo | 129 | 67 | 21 | •••@mit.edu | 617-25••• | In the CSV | |
| 8 | The Engine | Venture capital firm | Cambridge, United States | Hardware, Health care | Emvolon, Hyperlight, Kytopen | 4 | 81 | 29 | 3 | •••@engine.xyz | In the CSV | |
| 9 | Waterline Ventures | Venture capital firm | Cambridge, United States | Health care, Artificial intelligence | Manifold | 1 | 41 | 10 | 8 | •••@waterlineventures.com | (857) ••• | In the CSV |
| 10 | Mass General Brigham Ventures | Corporate venture arm | Cambridge, United States | Health care, Biotech | Claris Biotherapeutics, InStride Health | 2 | 39 | 4 | 6 | In the CSV | ||
| 11 | Flagship Pioneering | Venture capital firm | Cambridge, United States | Biotech, Health care | Inari, Prologue Medicines, Quotient Therapeutics | 288 | 104 | 72 | 617-86••• | In the CSV | ||
| 12 | Flint Capital | Venture capital firm | Cambridge, United States | Artificial intelligence, Hardware | Bluebricks, Antidote Health, Nokod Security | 101 | 36 | 18 | •••@flintcap.com | In the CSV | ||
| 13 | Link Ventures | Venture capital firm | Cambridge, United States | Commerce, Fintech | Enlaye, Blitzy, Dono | 3 | 71 | 27 | 6 | •••@linkventures.com | In the CSV | |
| 14 | MRL Ventures Fund | Corporate venture arm, Venture capital firm | Cambridge, United States | Biotech, Health care | InduPro | 1 | 52 | 8 | 14 | In the CSV | ||
| 15 | WuXi Healthcare Ventures | Venture capital firm | Cambridge, United States | Health care, Biotech | IMPACT Therapeutics, Nutrinia, Lumo Bodytech | 39 | 6 | 17 | •••@wuxiventures.com | (617) ••• | ||
| 16 | Accomplice | Family office, Venture capital firm | Cambridge, United States | Fintech, Artificial intelligence | Veera | 1 | 386 | 101 | 88 | •••@accomplice.co | 617-58••• | In the CSV |
| 17 | SBXi | Venture capital firm | Cambridge, United States | Health care, Hardware | SPORO Health, XanderGlasses, Basalt Tech | 196 | 0 | 6 | •••@sbxi.com | In the CSV | ||
| 18 | Rough Draft Ventures | Venture capital firm | Cambridge, United States | Artificial intelligence, Education | EdVisorly | 1 | 154 | 6 | 38 | 617-23••• | In the CSV | |
| 19 | Sanofi Ventures | Corporate venture arm | Cambridge, United States | Biotech, Health care | i2o Therapeutics, Tisento Therapeutics, NGI | 119 | 31 | 28 | •••@gmail.com | +1 617••• | In the CSV | |
| 20 | E14 Fund | Micro VC fund | Cambridge, United States | Artificial intelligence, Hardware | Ramona | 1 | 112 | 12 | 11 | •••@e14fund.com | +1 617••• | In the CSV |
| 21 | Romulus Capital | Venture capital firm | Cambridge, United States | Health care, Fintech | Albiware, Lora DiCarlo, Placester | 71 | 34 | 15 | •••@romuluscap.com | +1 888••• | In the CSV | |
| 22 | First Star Ventures | Venture capital firm | Cambridge, United States | Artificial intelligence, Biotech | Bot Auto, Blumen Systems, Oort | 58 | 9 | 9 | •••@firststar.vc | (707) ••• | In the CSV | |
| 23 | SpringTide Ventures | Venture capital firm | Cambridge, United States | Health care, Artificial intelligence | Prolucent Health, Leash Biosciences, Binkey | 43 | 12 | 6 | 801-82••• | In the CSV | ||
| 24 | Engine Ventures | Venture capital firm | Cambridge, United States | Artificial intelligence, Biotech | Trener Robotics, Addis Energy | 2 | 42 | 22 | 1 | •••@engineventures.com | 617-54••• | In the CSV |
| 25 | LSP BioVentures | Venture capital firm | Cambridge, United States | Biotech, Health care | Innovative Molecules, Luxendo, Affectis Pharmaceuticals | 29 | 14 | 18 | •••@yfcip.pbz | (781) ••• | In the CSV | |
| 26 | Gurnet Point Capital | Private equity firm, Venture capital firm | Cambridge, United States | Health care, Artificial intelligence | Fairtility, BEFORE Brands | 12 | 9 | 2 | •••@gurnetpointcapital.com | 617-58••• | In the CSV |
Table 2. Health care investors in Cambridge, Massachusetts: the first 26 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 26.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | Founder Collective | Cambridge, United States | 5 | 119 | Baselayer, WHOOP, Ownwell |
| 2 | F-Prime | Cambridge, United States | 4 | 75 | T-Therapeutics, Albert Invent, Immuneel Therapeutics |
| 3 | Matrix | Cambridge, United States | 4 | 109 | Houmo.AI, Ampersand, Outset |
| 4 | The Engine | Cambridge, United States | 4 | 9 | Emvolon, Hyperlight, Kytopen |
| 5 | Mission BioCapital | Cambridge, United States | 4 | 8 | Circle Pharma, Cloverleaf Bio, Integrated Biosciences |
| 6 | Link Ventures | Cambridge, United States | 3 | 14 | Enlaye, Blitzy, Dono |
| 7 | Mass General Brigham Ventures | Cambridge, United States | 2 | 4 | Claris Biotherapeutics, InStride Health |
| 8 | Engine Ventures | Cambridge, United States | 2 | 7 | Trener Robotics, Addis Energy |
| 9 | E14 Fund | Cambridge, United States | 1 | 20 | Ramona |
| 10 | MRL Ventures Fund | Cambridge, United States | 1 | 3 | InduPro |
| 11 | Rough Draft Ventures | Cambridge, United States | 1 | 29 | EdVisorly |
| 12 | Accomplice | Cambridge, United States | 1 | 47 | Veera |
| 13 | Atlas Venture | Cambridge, United States | 1 | 47 | Diagonal Therapeutics |
| 14 | Waterline Ventures | Cambridge, United States | 1 | 4 | Manifold |
Table 3. Health care investors in Cambridge, Massachusetts: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime | 51 to 100 | 2022 |
| Emvolon | Emvolon converts wasted resources into low-cost green fuels. | Energy | Woburn, United States | Series A | $22.0M | 2026-10-27 | $24.5M | The Engine | 11 to 50 | 2021 |
| Albert Invent | Albert Invent builds an AI platform that supports chemistry research and development for scientific and industrial users. | Artificial intelligence | Oakland, United States | Series B | $55.0M | 2026-10-13 | $105.0M | F-Prime | 101 to 250 | 2022 |
| Ampersand | Ampersand provides integration infrastructure for enterprise AI agents and software applications. | Artificial intelligence | San Francisco, United States | Series A | $15.0M | 2026-10-06 | $19.7M | Matrix | 11 to 50 | 2022 |
| Baselayer | Baselayer automates risk assessment and fraud detection for financial and government institutions. | Artificial intelligence | New York, United States | Series A | $35.0M | 2026-09-22 | $82.0M | Founder Collective | 51 to 100 | 2024 |
| Ramona | Ramona develops high-throughput microscopy tools for biology labs. | Artificial intelligence | Durham, United States | Series A | $25.0M | 2026-09-22 | $59.7M | E14 Fund | 11 to 50 | 2017 |
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco, United States | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital | 11 to 50 | 2012 |
| Cloverleaf Bio | Cloverleaf Bio develops an RNA therapeutic platform for oncology. | Biotech | New Haven, United States | Seed | $33.0M | 2026-09-08 | $33.0M | Mission BioCapital | 1 to 10 | 2023 |
| InduPro | InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. | Biotech | Seattle, United States | Series B | $77.0M | 2026-08-12 | $162.0M | MRL Ventures Fund | 51 to 100 | 2022 |
| Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City, United States | Series A | $68.4M | 2026-08-05 | $85.6M | Mission BioCapital | 11 to 50 | 2022 |
Table 4. Health care investors in Cambridge, Massachusetts: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 433 | 76% |
| Health care | 119 | 21% |
| Artificial intelligence | 108 | 19% |
| Hardware | 94 | 16% |
| Biotech | 70 | 12% |
| Fintech | 68 | 12% |
| Commerce | 52 | 9% |
| Cybersecurity | 42 | 7% |
| Education | 28 | 5% |
| Energy | 7 | 1% |
Table 5. Health care investors in Cambridge, Massachusetts: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Early stage investors | 24 | 92% |
| Seed investors | 20 | 77% |
| Late stage investors | 15 | 58% |
| Venture investors | 14 | 54% |
| Post IPO investors | 6 | 23% |
| Convertible note investors | 3 | 12% |
| Debt investors | 3 | 12% |
| Private equity investors | 2 | 8% |
Table 6. Health care investors in Cambridge, Massachusetts by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2010s | 13 | 50% |
| 2000s | 8 | 31% |
| 1990s | 1 | 4% |
| 1980s | 1 | 4% |
| 1970s | 2 | 8% |
| 1940s | 1 | 4% |
Table 7. Health care investors in Cambridge, Massachusetts by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when it is recorded as an investor in 2 or more funded health care companies and its headquarters is in Cambridge, Massachusetts. On 16 November 2026 that is 26 investors.
- 19 rows carry an email address and 18 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 26 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 26 rows: 0 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care investors in Cambridge, Massachusetts are on the list?
- 26, in the file dated 16 November 2026. 14 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 19 of the 26 carry an email address in the download and 18 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 26 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 26 rows, 19 firm email addresses and 18 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 11 of the 19 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.